Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 5/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.41 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13544182 | 0.79 | DDAH1 (0.44) | GAAHTTADORA1ADORA3ADORA2A | |
| SCHEMBL13544178 | 0.79 | GAA (0.42) | GAAHTTADORA1ADORA3ADORA2A | |
| SCHEMBL15381374 | 0.76 | PARP1 (0.39) | GAAADORA1ADORA3ADORA2ATNKS2 | |
| SCHEMBL12264335 | 0.74 | GAA (0.62) | GAAHTTDDAH1TNKS2IDO1 | |
| SCHEMBL27203429 | 0.72 | AR (0.32) | AR | |
| SCHEMBL29770337 | 0.72 | AR (0.32) | AR | |
| SCHEMBL12263999 | 0.71 | DDAH1 (0.53) | GAAHTTADORA1ADORA3ADORA2A | |
| SCHEMBL10248250 | 0.71 | L3MBTL1 (0.36) | ADORA1ADORA3ADORA2ASMN1; SMN2AR | |
| SCHEMBL22210595 | 0.70 | GAA (0.41) | GAAHTTADORA1ADORA3ADORA2A | |
| SCHEMBL4363225 | 0.69 | ADORA1 (0.54) | GAAHTTADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | Epizyme, Inc. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142625-A1 | Substituted Purine And 7-Deazapurine Compounds | TPMT, DIMT1, DAZAP1 | GAA 2247/4885HTT 2852/4885ADORA1 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.